Home » Topics » Regulatory » EMA

EMA
RSS

CHMP issues positive opinion on Avastin biosimilar ABP-215

Nov. 13, 2017

EMA committee recommends expanding approval of Orkambi

Nov. 13, 2017

EMA's CHMP supports expanding Nplate indication

Nov. 13, 2017

FDA gives orphan status to Achillion's ACH-4471 for PNH

Nov. 8, 2017

Pegfilgrastim biosimilar from Sandoz accepted for EMA review

Oct. 31, 2017

VBL Therapeutics' VB-111 granted orphan medicinal product status in E.U.

Oct. 23, 2017

EMA grants orphan drug designation to G-100 for the treatment of follicular non-Hodgkin's lymphoma

Oct. 20, 2017

EMA grants orphan drug designation to Conatus' IDN-7314 for primary sclerosing cholangitis

Oct. 19, 2017

Ignyta's entrectinib obtains PRIME designation from EMA

Oct. 18, 2017

EMA's CHMP supports expansion of marketing authorization for Zytiga

Oct. 16, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026